Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | BRD2 | P25440 | 3/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348128 | 0.77 | DGAT2 (0.66) | DGAT2CYP2C9P2RX3 | |
| SCHEMBL20166395 | 0.68 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL21523230 | 0.68 | DGAT2 (1.00) | DGAT2 | |
| SCHEMBL21048459 | 0.65 | CYP2C9 (0.48) | DGAT2CYP2C9P2RX3MEN1KMT2A | |
| SCHEMBL452072 | 0.65 | CYP2C9 (0.48) | DGAT2CYP2C9P2RX3MEN1KMT2A | |
| SCHEMBL3177746 | 0.65 | P2RX3 (0.59) | DGAT2CYP2C9P2RX3PPARG | |
| SCHEMBL19773478 | 0.61 | DGAT2 (0.88) | DGAT2CYP2C9PPARG | |
| SCHEMBL13095501 | 0.61 | P2RX3 (0.64) | DGAT2CYP2C9P2RX3 | |
| SCHEMBL13092847 | 0.60 | P2RX3 (0.72) | DGAT2CYP2C9P2RX3PPARG | |
| SCHEMBL12388526 | 0.60 | CYP2C9 (0.54) | DGAT2CYP2C9P2RX3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | DGAT2 3948/4885CYP2C9 4126/4885P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.